70. Assessment of circulating tumor DNA tumor mutational burden to define resistance in HR+ HER2- metastatic breast cancer

Identifying subsets of patients with baseline resistance to endocrine therapy (ET) combined with CDK4/6 inhibition (CDK4/6i) is challenging. Our study examined circulating tumor DNA (ctDNA) using whole-exome sequencing to derive blood tumor mutational burden (bTMB) and mutational signatures to assess patients with early progression on ET  + CDK4/6i.

Source: Cancer Genetics and Cytogenetics - November 1, 2022 Category: Genetics & Stem Cells Authors: Andrew A. Davis, Jingqin Luo, Tiantian Zheng, Xiaoxi Dong, Lu Tan, Amy Wang, Rama Suresh, Foluso Ademuyiwa, Caron Rigden, Timothy Rearden, Katherine Clifton, Katherine Weilbaecher, Ashley Frith, Pavan K. Tandra, Tracy Summa, Britney Haas, Shana Thomas, Le Source Type: research